

Anti-TNFSF5/CD40L/CD154 Antibody (Ruplizumab)

Introduction

Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1 κ antibody. Ruplizumab has the potential to be used in systemic lupus erythematosus disease research.

Product parameters

| | |
|---------------------|--|
| Alternative Names | BG-9588 |
| Target Accession | P29965 |
| Target | TNFSF5 / CD40L / CD154 |
| CAS number | 220651-94-5 |
| Molecular Weight | 145.68 kDa |
| Host | CHO |
| Reactivity | Human |
| Conjugation | Unconjugated |
| Form | Liquid |
| Concentration | See label |
| Buffer System | 100 mM Pro 20 mM Arg pH 5.0. No preservative! |
| Clonality | Monoclonal |
| Purification | Protein A |
| Isotype | IgG1 |
| Application | ELISA, FACS, Kinetics, Functional assay, Animal Model |
| Biological activity | - |
| Endotoxin | Less than 0.1 EU/ug determined by LAL method. |
| Sterilization | 0.2 μ M filtered |
| Reconstitution | For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex. |
| Shipping | Dry ice |
| Storage | -80°C |
| Expiration Date | 2 years |
| Note | Please avoid freeze-thaw cycles. |

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

